Free Newsletter
Pharma plays chicken with U.K. prices
Last month, the Brits ripped up their pharmaceuticals pricing agreement and demanded to renegotiate. This month, Big Pharma strikes back. The Association of the British Pharmaceutical Industry claims that changes in the pricing scheme will cause big layoffs among drugmakers. And an industry poll showed that drugmakers expect U.K. conditions to deteriorate (83 percent) and that they plan to cut R&D investment, reduce spending on buildings and equipment, cut the number of clinical trials in the U.K., and reduce their level of manufacturing. Really. They will. Unless the government pays, they promise they absolutely will.
Of course the ABPI admits that Big Pharma already is in the midst of layoffs. Should we remind them that outsourcing and plant closures were already in the works, too?
- read the Telegraph article
- see the survey at Pharmalot
- get more in Forbes
Related Articles:
Pact adds cost effectiveness to drug study. Report
U.K. aims to slice drug prices 10%. Report
U.K. accepts J&J's money-back guarantee. Report
NHS fights expensive Alzheimer's drugs. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: